We have read with interest the study by Li and colleagues (1) on single nucleotide polymorphisms (SNPs) predicting brain metastases in non-small-cell lung cancer (NSCLC). Patients with the GT/GG genotype of AKT1-rs2498804, CT/TT of AKT1-rs2494732, and AG/AA of PIK3CA-rs2699887 had higher risk of brain metastasis.
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These data support the feasibility of studying germinal polymorphisms for risk stratification. However, several points should be discussed in more detail.
Firstly, the choice to focus on NSCLC is valuable, as treatment with prophylactic cranial irradiation is a matter of debate in this tumor. However, according to the "rule of tens", in a multivariate analysis there should be a minimum of 10 events per predictor variable.
As 16 SNPs were analysed, a total of 160 patients would have to have brain metastases in order to prevent overfitting, since the results from an overfitted model are not generalisable to other populations. Another critical obstacle to the successful development of a genotype-based test is the high number of spurious associations (2).
To avoid false-positive associations, a Bonferroni correction considering all the studied SNPs would require a P<0.05/16=0.003 for statistical significance.
Emerging SNPs need to be validated in independent cohorts, and our dataset from stage-IIIB/IV NSCLC (3) confirmed the association of AKT1-rs2498804, but not of PIK3CA:rs2699887, with brain metastases (Table 1) . These conflicting data might be In conclusion, we thank Li and collaborators for their study, but we believe that additional parameters are essential to validate candidate SNPs beyond already available clinical factors for predicting brain metastases in NSCLC. Tables   Table 1. Polymorphisms and brain metastases in advanced  NSCLC patients treated with gefitinib   Polymorphism Patients, N Events, N (%) P value*
